Loading clinical trials...
Loading clinical trials...
A Feasibility Study to Evaluate the Safety And Tolerability of the EPI-RAD90™ Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization (CNV) in Patients With Age-Related Macular Degeneration (AMD) That Have Failed Primary Anti-VEGF Therapy
Conditions
Interventions
NeoVista Ophthalmic System
Locations
2
United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States
Medical Center Ophthalmology Associates
San Antonio, Texas, United States
Start Date
December 1, 2007
Primary Completion Date
June 1, 2011
Completion Date
June 1, 2011
Last Updated
July 27, 2011
NCT06718816
NCT04932980
NCT07389577
NCT05381948
NCT03585556
NCT06398080
Lead Sponsor
NeoVista
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions